Acute Coronary Syndrome: Optimizing Outcomes Across the Spectrum of Care™—An Evidence-Based Best Practices Program-ACS presents a major healthcare challenge. This year, more than 1 million adults will experience a new or recurrent episode of unstable angina (UA), non-ST-segment-elevation myocardial infarction (NSTEMI), or ST-segment-elevation myocardial infarction (STEMI)—the 3 clinical manifestations of ACS. Although recent data show declines in the incidence and associated mortality of ACS, opportunities exist to further improve diagnostic and management approaches. First, suboptimal utilization of validated risk assessment tools and inadequate incorporation of guideline recommendations contribute to under-treatment. Second, while platelet-rich thrombus formation is central to ACS, important questions remain about the timing and duration of platelet inhibition, and approaches to minimize bleeding risk. Multiple combinations of oral antiplatelet agents are now available with different risk/benefit profiles, particularly in high-risk settings such as STEMI and diabetes. Finally, US and European guidelines differ in how individual combinations are codified. Accordingly, international faculty will address best practices in the evidence-based assessment and individualized treatment of ACS.-Describe the pathophysiology of ACS and its implications for platelet inhibition, particularly during angiography with/without stenting
Identify patients with ACS who are at high risk for bleeding and select antiplatelet therapy accordingly
Utilize platelet function testing and/or genotyping in select patients at risk for recurrent thrombotic events
Select appropriate antiplatelet therapy for patients with ACS, continually integrating Level 1 evidence with clinical evaluation of risks and benefits
Coordinate care of patients with primary care physicians following discharge
1.0 Free Pra CAT 1 AMA CEUs for Physicians
Expires 2/5/13